Antidepressant therapy guided by the GeneSight Psychotropic genetic test is 50% more likely to push the depression into remission and 30% more likely to achieve treatment response compared to therapy not guided by the genetic test, according to results of the IMPACT trial, which were presented at the American Psychiatric Association annual meeting in New York on May 7.
The GeneSight test, developed by Myriad Genetics Inc.' subsidiary Assurex Health Inc., is a pharmacogenomic assay of genomic variants that are associated with especially good, or especially poor,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?